Tratamiento del infarto agudo de miocardio en el Perú y su relación con eventos adversos intrahospitalarios: resultados del segundo registro peruano de infarto de miocardio con elevación del segmento ST (PERSTEMI-II)

Manuel Chacón-Diaz, René Rodríguez Olivares, David Miranda Noé, Piero Custodio-Sánchez, Alexander Montesinos Cárdenas, Germán Yábar Galindo, Aida Rotta Rotta, Roger Isla Bazán, Paol Rojas de la Cuba, Nassip Llerena Navarro, Marcos López Rojas, Mauricio García Cárdenas, Akram Hernández Vásquez

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

10 Citas (Scopus)

Resumen

Background. ST-segment elevation myocardial infarction (STEMI), is an important cause of morbidity and mortality worldwide, and myocardial reperfusion, when adequate, reduces the complications of this entity. The aim of the study was to describe the clinical and treatment characteristics of STEMI in Peru and the relationship of successful reperfusion with in-hospital adverse events. Materials and methods. Prospective, multicenter cohort of STEMI patients attended during 2020 in public hospitals in Peru. We evaluated the clinical, therapeutic characteristics and in-hospital adverse events, also the relationship between successful reperfusion and adverse events. Results. A total of 374 patients were included, 69.5% in Lima and Callao. Fibrinolysis was used in 37% of cases (pharmacoinvasive 26% and fibrinolysis alone 11%), primary angioplasty with < 12 hours of evolution in 20%, late angioplasty in 9% and 34% did not access adequate reperfusion therapies, mainly due to late presentation. Ischemia time was longer in patients with primary angioplasty compared to fibrinolysis (median 7.7 hours (RIQ 5-10) and 4 hours (RIQ 2.3-5.5) respectively). Mortality was 8.5%, the incidence of post-infarction heart failure was 27.8% and of cardiogenic shock 11.5%. Successful reperfusion was associated with lower cardiovascular mortality (RR:0.28; 95%CI: 0.12-0.66, p=0.003) and lower incidence of heart failure during hospitalization (RR: 0.61; 95%CI: 0.43-0.85, p=0.004). Conclusions. Fibrinolysis continues to be the most frequent reperfusion therapy in public hospitals in Peru. Shorter ischemia-to-reperfusion time was associated with reperfusion success, and in turn with fewer in-hospital adverse events.

Título traducido de la contribuciónTreatment of acute myocardial infarction in Peru and its relationship with in-hospital adverse events: results from the second peruvian registry of ST-segment elevation myocardial infarction (PERSTEMI-II)
Idioma originalEspañol
Páginas (desde-hasta)86-95
Número de páginas10
PublicaciónArchivos Peruanos de Cardiologia y Cirugia Cardiovascular
Volumen2
N.º2
DOI
EstadoPublicada - 30 jun. 2021
Publicado de forma externa

Palabras clave

  • Angioplasty
  • Fibrinolysis
  • Mortality
  • Myocardial Infarction
  • Peru

Huella

Profundice en los temas de investigación de 'Tratamiento del infarto agudo de miocardio en el Perú y su relación con eventos adversos intrahospitalarios: resultados del segundo registro peruano de infarto de miocardio con elevación del segmento ST (PERSTEMI-II)'. En conjunto forman una huella única.

Citar esto